Medicinal agents and metabolic syndrome
M E Rubio-Ruiz1, M El Hafidi, I Pérez-Torres
1Department of Physiology, Instituto Nacional de Cardiología Ignacio Chávez, México, D.F.
Current Medicinal Chemistry
|April 18, 2013
Summary
Metabolic Syndrome (MS) is a growing epidemic defined by conditions like hypertension and obesity. Lifestyle changes, including exercise and diet, alongside medications, are key to managing this multifaceted health issue.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- Metabolic Syndrome (MS) lacks a universal definition but is characterized by hypertension, obesity, dyslipidemia, insulin resistance, inflammation, and renal damage.
- The global incidence of MS is increasing, approaching epidemic proportions.
- A consensus suggests three or more of these pathologies define MS.
Purpose of the Study:
- To explore the multifaceted nature of Metabolic Syndrome.
- To review current and emerging therapeutic strategies for MS management.
Main Methods:
- Literature review of established and novel treatments for MS components.
- Analysis of lifestyle interventions, including diet and exercise.
- Examination of pharmacological approaches and their anti-inflammatory effects.
Main Results:
- Regular exercise demonstrates anti-inflammatory effects by reducing inflammatory biomarkers.
- Mediterranean diet, rich in antioxidants and unsaturated oils, is recommended.
- Pharmaceuticals targeting obesity, hypertension, dyslipidemia, and diabetes are common treatments.
- Emerging evidence highlights the anti-inflammatory properties of statins, fibrates, metformin, and thiazolidinediones in MS treatment.
Conclusions:
- Metabolic Syndrome requires a comprehensive management approach.
- Lifestyle modifications and pharmacological interventions play crucial roles.
- Further research into the anti-inflammatory mechanisms of existing drugs may offer new therapeutic avenues for MS.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:21Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in determining the metabolic...
The drug's acidity or basicity is essential in determining the metabolic...